MedTrace Logo

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

NCT04731909 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2021-02-10

No results posted yet for this study

Summary

To evaluates the effectiveness and safety of Toripalimab combined with Anlotinib and chemotherapy for the first-line treatment of ES-SCLC, and maintenance therapy are Toripalimab combined with Anlotinib.

Conditions

Interventions

DRUG

Toripalimab

Toripalimab 240mg,ivgtt,d1,q3w.

DRUG

Anlotinib

Anlotinib 12 mg/d,d1-14,q3w,4-6 cycles in total. In maintenance treatment period, Anlotinib 12 mg/d,d1,Oral for 2 weeks and stop for 1 week.

DRUG

Cisplatin

75mg/m2,d1,q3w,4-6 cycles in total.

DRUG

Carboplatin

AUC=5,d1,q3w,4-6 cycles in total.

Sponsors & Collaborators

  • Third Military Medical University

    lead OTHER

Principal Investigators

  • Dong Wang, PH.D · Daping Hospital, Third Military Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2022-06-01
Completion
2023-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04731909 on ClinicalTrials.gov